Ticker
ALEC

Price
6.34
Stock movement down
-0.03 (-0.47%)
Company name
Alector Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
526.40M
Ent value
945.28M
Price/Sales
3.94
Price/Book
2.45
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-33.54%
3 year return
-32.75%
5 year return
-20.35%
10 year return
-
Last updated: 2024-02-20

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ALEC does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.94
Price to Book2.45
EV to Sales7.07

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count83.03M
EPS (TTM)-1.62
FCF per share (TTM)-0.30

Income statement

Loading...
Income statement data
Revenue (TTM)133.62M
Gross profit (TTM)119.18M
Operating income (TTM)-137.83M
Net income (TTM)-133.31M
EPS (TTM)-1.62
EPS (1y forward)-2.22

Margins

Loading...
Margins data
Gross margin (TTM)89.19%
Operating margin (TTM)-103.16%
Profit margin (TTM)-99.77%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash154.32M
Net receivables0.00
Total current assets726.43M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets787.65M
Accounts payable4.19M
Short/Current long term debt43.33M
Total current liabilities93.81M
Total liabilities573.21M
Shareholder's equity214.44M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-20.33M
Capital expenditures (TTM)4.12M
Free cash flow (TTM)-24.45M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-62.17%
Return on Assets-16.93%
Return on Invested Capital-59.91%
Cash Return on Invested Capital-10.99%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.29
Daily high6.54
Daily low6.25
Daily Volume460K
All-time high39.49
1y analyst estimate14.78
Beta0.83
EPS (TTM)-1.62
Dividend per share-
Ex-div date-
Next earnings date26 Feb 2024

Downside potential

Loading...
Downside potential data
ALECS&P500
Current price drop from All-time high-83.95%-1.05%
Highest price drop-90.45%-56.47%
Date of highest drop13 Nov 20239 Mar 2009
Avg drop from high-53.93%-11.40%
Avg time to new high58 days13 days
Max time to new high660 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ALEC (Alector Inc) company logo
Marketcap
526.40M
Marketcap category
Small-cap
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Employees
273
Investor relations
-
SEC filings
CEO
Arnon Rosenthal
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...